Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 28, 2023 08:15 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals to Present PCS12852 Gastroparesis Results at the Digestive Disease Week 2023 Annual Meeting

PCS12852 Shown to be Safe and Efficacious in Phase 2 Proof-of-Concept Trial in Gastroparesis PatientsPCS12852 Improved Both Gastroparesis Symptom Scores and Gastric Emptying Rate HANOVER, MD, April ...
November 08, 2022 08:30 ET | Source: Processa Pharmaceuticals, Inc.

PCS12852 Improves Gastric Emptying in Gastroparesis Patients

In a Phase 2A Proof-of-Concept trial, the Gastric Emptying Breath Test (GEBT) results demonstrated statistical improvement in gastric emptying in gastroparesis patients receiving 0.5 mg of PCS12852 (6...
September 15, 2022 08:30 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals Provides Update on Enrollment Across all Clinical Programs

PCS12852 for Gastroparesis concluded enrollment a month ahead of schedule. Statistics on gastric emptying, safety and GEBT data will be available by the end of October and full topline data is...
September 07, 2022 08:30 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 12-14, 2022

HANOVER, MD, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality...
May 05, 2022 08:30 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals to Host Conference Call to Discuss First Quarter 2022 Results and Provide Drug Development Update on May 12, 2022 at 4:30 p.m. EST

HANOVER, MD, May 05, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of...
March 23, 2022 08:30 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals To Host Conference Call to Discuss Fourth Quarter 2021 Results and Provide Drug Development Update on March 30 at 4:30 p.m. EST

HANOVER, MD, March 23, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality...
August 12, 2021 17:15 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals Announces Second Quarter 2021 Results and Provides Corporate Update

Adds fourth clinical asset, RX-3117, and targets major milestones in the second half of 2021 HANOVER, Md., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a...
May 20, 2021 16:05 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals Announces First Patient Dosed in its Randomized Double-Blind, Placebo-Controlled Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica

~Processa’s trial is currently enrolling patients with ulcerated Necrobiosis Lipoidica. Detailed information on the trial can be located on clinicaltrials.gov NCT#: 04800562.~ HANOVER, MD., May 20,...
March 22, 2021 09:15 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter Results and Provide Drug Development Update on March 25 at 5:30 p.m. ET

HANOVER, MD., March 22, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to...